title: Clinical utility of RAS mutations in thyroid cancer: a blurred picture now emerging clearer.
abstract: RAS mutations play an important role in thyroid tumorigenesis. Considerable effort has been made in the last decade to apply RAS mutations as molecular markers to the clinical management of thyroid nodules and thyroid cancer. Yet, for the low diagnostic sensitivities and specificities of RAS mutations, when used alone, and for their uncertain role in the clinical outcomes of thyroid cancer, it has been unclear how to appropriately use them to assist the management of thyroid nodules and thyroid cancer. Studies from recent years, now added from the Alexander group, have shed light on this issue, making a blurred clinical picture now emerge clearer-RAS mutations, when combined with other genetic markers, have high diagnostic negative predictive values for thyroid cancer; cytologically benign thyroid nodules, including those positive for RAS mutations, have long-term clinical stability when non-surgically managed; and differentiated thyroid cancers harboring RAS mutations alone have an excellent prognosis. This progress in understanding RAS mutations in thyroid cancer is showing a major impact on molecular-based practice in the management of thyroid cancer.Please see related research articles: http://dx.doi.org/10.1186/s12916-016-0554-1 and http://dx.doi.org/10.1186/s12916-015-0419-z.
authors.affiliation: Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA. mxing1@jhmi.edu.
authors.forename: Mingzhao
authors.initials: M
authors.lastname: Xing
mesh_terms: D005260:Female; D006801:Humans; D008297:Male; D016606:Thyroid Nodule
references.citation: N Engl J Med. 2012 Aug 23;367(8):705-15
references.pmid: 22731672
references.citation: J Clin Endocrinol Metab. 2009 Dec;94(12):4735-41
references.pmid: 19837916
references.citation: JAMA. 2015 Mar 3;313(9):926-35
references.pmid: 25734734
references.citation: BMC Med. 2016 Jan 27;14:11
references.pmid: 26817603
references.citation: Endocr Relat Cancer. 2014 Oct;21(5):825-30
references.pmid: 25121551
references.citation: Mol Cell Endocrinol. 2015 Jan 5;399:288-95
references.pmid: 25448848
references.citation: J Clin Oncol. 2003 Sep 1;21(17):3226-35
references.pmid: 12947056
references.citation: J Clin Endocrinol Metab. 2005 Dec;90(12):6373-9
references.pmid: 16174717
references.citation: Endocr Relat Cancer. 2016 Mar;23(3):R143-55
references.pmid: 26733501
references.citation: Cancer Res. 2009 Apr 15;69(8):3689-94
references.pmid: 19351816
references.citation: JAMA. 2013 Apr 10;309(14):1493-501
references.pmid: 23571588
references.citation: Cancer. 2014 Dec 1;120(23):3627-34
references.pmid: 25209362
references.citation: J Clin Endocrinol Metab. 2011 Nov;96(11):3390-7
references.pmid: 21880806
references.citation: Thyroid. 2014 Oct;24 Suppl 1:A131-9
references.pmid: 25340533
references.citation: Oncogene. 1988 Apr;2(4):403-6
references.pmid: 3283656
references.citation: Nat Rev Cancer. 2011 Oct 13;11(11):761-74
references.pmid: 21993244
references.citation: Cell. 2014 Oct 23;159(3):676-90
references.pmid: 25417114
references.citation: BMC Med. 2015 Aug 07;13:184
references.pmid: 26253102
references.citation: Thyroid. 2014 Oct;24(10):1479-87
references.pmid: 24811481
references.citation: Nat Rev Cancer. 2013 Mar;13(3):184-99
references.pmid: 23429735
references.citation: Oncologist. 2013;18(8):926-32
references.pmid: 23873720
references.citation: Endocr Relat Cancer. 2013 Jul 12;20(4):603-10
references.pmid: 23766237
references.citation: Thyroid. 2010 Jul;20(7):697-706
references.pmid: 20578891
references.citation: Oncogene. 2005 Oct 6;24(44):6646-56
references.pmid: 16007166
references.citation: Nat Commun. 2013;4:2185
references.pmid: 23887589
references.citation: Am J Clin Pathol. 2009 Nov;132(5):658-65
references.pmid: 19846805
references.citation: N Engl J Med. 1993 Feb 25;328(8):553-9
references.pmid: 8426623
references.citation: Eur J Clin Invest. 2009 Aug;39(8):699-706
references.pmid: 19601965
references.citation: Thyroid. 2016 Jan;26(1):1-133
references.pmid: 26462967
references.citation: J Clin Oncol. 2015 Jan 1;33(1):42-50
references.pmid: 25332244
references.citation: J Clin Oncol. 2014 Sep 1;32(25):2718-26
references.pmid: 25024077
references.citation: Thyroid. 2012 Jul;22(7):683-9
references.pmid: 22650231
references.citation: Lancet. 2013 Mar 23;381(9871):1058-69
references.pmid: 23668556